Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Active not recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 7Thoracic 5Gynecologic 5CNS 4Head & Neck 3Sarcoma 2Gastrointestinal 2Breast 2Other hematologic neoplasm 1Myeloid 1

Conditions

Triple-negative Metastatic Breast Cancer 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × adavosertib × Breast × Clear all
NCT02482311 2023-07-03

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
92 enrolled
BreastGynecologicThoracic

Ovarian Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03012477 2021-11-23

CISPLATIN + AZD-1775 In Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Completed
34 enrolled 9 charts
Breast

Triple-negative Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡